Consolidated figures · ₹ crore
| ₹ Cr | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| 14,253 | 15,102 | 15,265 | 17,237 | 19,547 | 23,242 | 27,148 | |
| COGS | 4,920 | 5,210 | 5,545 | 6,310 | 6,228 | 6,338 | 7,293 |
| Gross profit | 9,333 | 9,892 | 9,720 | 10,927 | 13,319 | 16,904 | 19,856 |
| 6,521 | 6,504 | 6,333 | 6,973 | 7,817 | 9,787 | 11,284 | |
| 2,812 | 3,388 | 3,387 | 3,955 | 5,503 | 7,116 | 8,572 | |
| OPM % | 19.7% | 22.4% | 22.2% | 22.9% | 28.2% | 30.6% | 31.6% |
| Depreciation | 697 | 725 | 713 | 723 | 764 | 916 | 1,408 |
| Interest | 342 | 164 | 127 | 130 | 81 | 166 | 439 |
| -250 | -168 | 2,583 | -422 | 293 | 50 | -7 | |
| Profit before tax | 1,524 | 2,332 | 5,130 | 2,680 | 4,950 | 6,085 | 6,718 |
| Tax | 320 | 147 | 512 | 588 | 978 | 1,412 | 1,595 |
| Tax % | 21% | 6.3% | 10% | 21.9% | 19.8% | 23.2% | 23.7% |
| 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | 5,124 | |
| PAT margin % | 8.5% | 14.5% | 30.3% | 12.1% | 20.3% | 20.1% | 18.9% |
| EPS (₹) | 11.5 | 20.8 | 43.8 | 19.3 | 38.1 | 45 | 50.1 |
| EPS adjusted (₹) | 11.5 | 20.8 | 43.8 | 19.4 | 1.1 | 1.5 | 50.1 |
| 30.5% | 16.8% | 5.7% | 31.1% | 7.9% | 24.5% | 2% | |
| Annual report | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | Annual report for Mar 2026 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 101 |
| Reserves | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,853 | 27,011 |
| Minority interest | — | — | — | — | 1,937 | 2,054 | 2,173 | 2,272 | 2,405 | 2,471 |
| 4,945 | 5,113 | 7,147 | 7,041 | 4,584 | 4,196 | 1,163 | 769 | 3,170 | 11,770 | |
| 3,315 | 4,208 | 5,950 | 6,270 | 4,372 | 4,546 | 4,905 | 6,411 | 7,674 | 11,055 | |
| Total equity & liabilities | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 | 52,407 |
| 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,253 | 11,521 | 12,369 | 13,134 | 24,106 | |
| CWIP | 1,543 | 1,527 | 837 | 742 | 783 | 661 | 1,130 | 1,112 | 1,318 | 1,166 |
| Investments | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 | 6,408 | 7,540 |
| 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,559 | 14,580 | 16,342 | 19,595 | |
| Total assets | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 | 52,407 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Pharmaceuticals | 22,412.1 | 7,048.8 | 35,798.3 | 11,968.4 | 23,829.9 | 29.58 |
| Consumer products | 3,954 | 267.1 |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,312 | 919 | 1,282 | 2,932 | 3,293 | 2,078 | 2,689 | 3,228 | 6,777 | 2,117 | |
| -2,872 | -974 | -4,239 | -1,012 | -830 | 1,154 | 1,171 | -1,475 | -8,372 | -8,296 | |
| 2,316 | 52 | 1,885 | -1,528 | -2,549 | -868 | -4,400 | -1,804 | 2,031 | 5,997 | |
| Net cash flow | 756 | -3 | — | 391 | -86 | 2,364 | -540 | -52 | 435 | -182 |
| Free cash flow | -1,628 | -130 | 225 | 2,027 | 2,439 | 876 | 1,658 | 2,321 | 5,064 | -1,277 |
| CFO / Operating profit % | — | — | — | 105.3% | 98.6% | 62.2% | 69.7% | 60% | 96% | 25% |
| 10,306.2 |
| 4,479 |
| 5,827.2 |
| 4.58 |
| Medical technologies | 782.3 | -178.2 | 6,302.1 | 6,377 | — | — |
₹ crore by fiscal year